UW to collaborate on biodefense drug development

The Gale Lab in partnership with the University of Texas Medical Branch at Galveston and a Seattle biotech company, Kineta Inc. received an $8.1 million biodefense grant that will fund the development of new drugs to treat some of the world’s most dangerous diseases, including Ebola, plague, Japanese encephalitis and other lethal pathogens.  Please see the press release at: